Neuropeptide Y and its involvement in chronic pain

TL;DR

This paper reviews the role of Neuropeptide Y in modulating pain, highlighting its potential as a target for developing new treatments for chronic pain conditions.

Contribution

It summarizes current knowledge on NPY's involvement in pain modulation and discusses its potential for future therapeutic applications.

Findings

NPY has both pro- and antinociceptive effects.

Intrathecal NPY administration reduces pain in animal models.

Mechanisms of NPY's analgesic effects remain unclear.

Abstract

Chronic pain is a serious condition that significantly impairs the quality of life, affecting an estimate of 1.5 billion people worldwide. Despite the physiological, emotional and financial burden of chronic pain, there is still a lack of efficient treatments. Neuropeptide Y (NPY) is a highly conserved endogenous peptide in the central and peripheral nervous system of all mammals, which has been implicated in both pro- and antinociceptive effects. NPY is expressed in the superficial laminae of the dorsal horn of the spinal cord, where it appears to mediate its antinociceptive actions via the Y1 and Y2 receptors. Intrathecal administration of NPY in animal models of neuropathic, inflammatory or post-operative pain has been shown to cause analgesia, even though its exact mechanisms are still unclear. It remains to be seen whether these promising central antinociceptive effects of NPY can be transferred into a future treatment for chronic pain.